Jiangsu wuzhong(SH:600200) Jin Rong Shi Bao·2025-07-16 01:37Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu) faces potential delisting due to continuous financial fraud over four years, with the China Securities Regulatory Commission (CSRC) proposing a fine of 10 million yuan and indicating a "zero tolerance" policy towards such violations [1][5]. Group 1: Financial Misconduct - *ST Suwu has been found to have inflated revenue by 4.95 billion yuan, 4.69 billion yuan, 4.31 billion yuan, and 3.77 billion yuan from 2020 to 2023, representing 26.46%, 26.39%, 21.26%, and 16.82% of reported revenue respectively [2]. - The company also inflated total profits by 14.58 million yuan, 20.27 million yuan, 19.92 million yuan, and 21.22 million yuan during the same period, accounting for 2.89%, 51.65%, 26.42%, and 29.81% of total profits respectively [2]. - Non-operational fund occupation by related parties amounted to 1.27 billion yuan, 1.39 billion yuan, 1.54 billion yuan, and 1.69 billion yuan from 2020 to 2023, which constituted 6.88%, 74.2%, 84.6%, and 96.09% of the reported net assets [2]. Group 2: Regulatory Actions - The CSRC plans to impose a total fine of 30.5 million yuan on *ST Suwu and its responsible individuals, with the actual controller, Qian Qunshan, facing a proposed 10-year ban from the securities market due to severe misconduct [3]. - Starting July 14, *ST Suwu's stock will be subject to delisting risk warnings due to its financial fraud, following previous warnings and a lack of opinion from the auditing firm on its 2024 financial report [4]. - The CSRC has demonstrated a firm stance against financial fraud in the market, as seen in other cases like Yuandao Communication, which is also under investigation for similar violations [5][6].